Semax 11mg

Source: https://pubmed.ncbi.nlm.nih.gov/16996037/

Scientific Findings

This study examined whether Semax influences BDNF production and its receptor TrkB in the hippocampus — the brain region most closely associated with learning and memory. Following a single intranasal application of Semax at 50 mcg/kg, researchers measured a 1.4-fold increase in BDNF protein levels, a 1.6-fold increase in TrkB receptor activation, a 3-fold increase in BDNF gene expression, and a 2-fold increase in TrkB gene expression in hippocampal tissue. Animals treated with Semax also showed a measurable increase in conditioned avoidance reactions — a standard behavioral measure of learning. The researchers concluded that Semax influences cognitive brain function by modulating the BDNF/TrkB signaling system in the hippocampus.

Plain English Summary

This is one of the most cited studies in Semax research. It found that a single dose produced a significant and rapid increase in the brain's own "growth factor" — BDNF — in the memory center of the brain. BDNF is the protein that helps brain cells grow, form new connections, and survive under stress. The animals treated with Semax also showed improved learning behavior. In plain terms, this study provides one of the clearest mechanistic explanations for why Semax is so widely studied as a cognitive and neuroprotective compound.

Source: https://pubmed.ncbi.nlm.nih.gov/16635254/

Scientific Findings This study investigated whether Semax has specific binding sites in the brain — a critical question for understanding how it works at the molecular level — and whether it affects BDNF protein levels in the basal forebrain, a region essential to attention and memory. Using tritium-labeled Semax, researchers confirmed that the peptide binds to specific, saturable sites on brain cell membranes in a time-dependent and reversible manner. The binding was calcium-dependent with a dissociation constant of 2.4 nM, indicating high-affinity interaction. Intranasal Semax at both doses tested produced a statistically significant increase in BDNF protein levels in the basal forebrain within 3 hours. Critically, this effect was region-specific — no increase was seen in the cerebellum — indicating that Semax targets brain areas most relevant to cognitive function rather than affecting the entire brain indiscriminately.

Plain English Summary This study answered a fundamental question about Semax: does it actually bind to something specific in the brain, or does it just float around? The answer was clear — Semax has specific docking points on brain cell membranes, and when it binds to them, BDNF levels rise rapidly in the memory and attention regions of the brain. The fact that this effect was seen in cognitively relevant brain areas but not in unrelated regions like the cerebellum suggests Semax acts in a targeted rather than broad-spectrum way — an important finding for researchers studying its precise mechanisms.

Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC11498467/

Scientific Findings

This study examined how Semax affects the expression of neurotrophin genes — proteins essential for brain cell survival — under conditions of focal cerebral ischemia, a model used to simulate stroke in research settings. Using a permanent middle cerebral artery occlusion model in rats, researchers measured the gene expression of BDNF, NGF, NT-3, and their corresponding receptors in the brain's cortex at 3, 24, and 72 hours following the ischemic event. Semax treatment significantly upregulated the transcription of BDNF and its receptor TrkC at 3 hours, followed by NGF and NT-3 at 24 hours — activating a coordinated cascade of brain cell survival signals at precisely the time points when ischemic tissue remains most vulnerable but potentially salvageable. This was the first study to demonstrate that Semax activates a coordinated, time-specific neurotrophin gene expression program in ischemia-damaged brain tissue.

Plain English Summary

During a stroke, brain cells begin dying rapidly as blood flow is cut off. This study showed that Semax responds to that crisis by switching on a timed sequence of genes that produce survival proteins for brain cells — activating them at exactly the windows when damaged tissue still has a chance to recover. In plain terms, rather than simply boosting one brain chemical, Semax appears to trigger a coordinated rescue response at the genetic level. This is one of the key reasons Semax has been clinically used in Russia for stroke recovery for decades, and why it continues to attract research interest in neuroprotection.